Xcout Intel
Muna Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Muna Therapeutics among biotechnology companies — ranked by similarity to what Muna Therapeutics actually does, not by market-cap band.
Subscribe to see Muna Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Muna Therapeutics
Muna Therapeutics is a privately held biopharmaceutical company founded in 2020 with headquarters in Copenhagen, Denmark, and operations in Leuven. The company discovers and develops novel therapies aimed at slowing or stopping devastating neurodegenerative diseases like Alzheimer's and Parkinson's.
Muna Therapeutics at a glance
Muna Therapeutics is a biotechnology company headquartered in Denmark. Its most recent funding round, Series A, raised $73M in July 2021. Xcout tracks 9 named people at Muna Therapeutics, including Michel Detheux (Chief Executive Officer & Board Director).
Muna Therapeutics leadership
- Michel DetheuxChief Executive Officer & Board Director
- LUC DOCHEZDroia Ventures
- Donald NicholsonIndependent Chair
- Rita Balice-GordonIndependent Director
- Camilla HansenNovo Holdings
- Cillian KingEQT
3 more named people on record for Muna Therapeutics, with roles, board committees and tenure — see the full roster →
Muna Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $73M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Muna Therapeutics competitors
Ranked by semantic similarity — how close each company is to Muna Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotech
Neumirna Therapeutics is a biotechnology company founded in 2021 and headquartered in Copenhagen, Denmark. The firm is dedicated to pioneering RNA-based therapies to treat epilepsy, Parkinson's disease, and other neurological disorders.
Similar biotechnology company
CuraSen Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapies to treat neurodegenerative diseases by targeting specific receptor systems in the brain. The company's scientific approach focuses on restoring neurovascular and neuronal function to serve patients suffering from conditions such as Parkinson's disease and other neurodegenerative disorders.
Similar biotechnology company
FoldLogic Bio is a clinical-stage biotechnology company developing targeted immunotherapies for neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and Multiple System Atrophy. The company focuses on modulating the central nervous system's immune responses, specifically targeting microglial activity, alpha-synuclein, and TREM2 to halt disease progression.
Biotech
Neumora Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for brain diseases, including neuropsychiatric and neurodegenerative disorders. It uses neuroscience, data science, and biomarkers to identify and advance treatments for patients with these conditions.
Similar biotechnology company
Arkuda Therapeutics is a biotechnology company developing small-molecule treatments for neurodegenerative diseases, with a focus on restoring lysosomal function and addressing progranulin-related disease biology. Its programs are aimed particularly at patients with frontotemporal dementia and other disorders involving lysosomal dysfunction.
Similar biotechnology company
BioArctic AB is a Swedish biopharmaceutical company developing disease-modifying treatments for neurodegenerative disorders, particularly Alzheimer’s and Parkinson’s disease. It serves patients and healthcare systems through its own drug-development programs and partnerships with pharmaceutical companies, including Eisai.
Similar biotechnology company
AriBio is a clinical-stage biopharmaceutical company founded in 2010 and headquartered in Seongnam, South Korea, with additional offices in the United States. The company focuses on developing novel therapeutics for neurodegenerative diseases.
Similar biotechnology company
Neurona Therapeutics Inc. is a biotherapeutics company that focuses on developing cell-based therapies to address neurological disorders.
Similar biotechnology company
Cognition Therapeutics, Inc. is a public, clinical-stage biopharmaceutical company founded in 2007 and headquartered in Purchase, New York. The company develops therapies designed to protect neurons and advance treatments for patients living with age-related neurodegenerative diseases.
Life Sciences
EXCIVA GmbH is a privately held biotechnology company established in 2016 in Heidelberg, Germany, focused on developing clinical-stage therapeutics to improve quality of life and treat Alzheimer's disease.
Biotech
BioArctic AB (publ) is an innovative Swedish research-based biopharma company headquartered in Stockholm, Sweden. Incorporated in 2000, it focuses on developing disease-modifying treatments for neurodegenerative diseases. The company is publicly traded and committed to corporate governance.
Similar biotechnology company
Myrobalan Therapeutics is a pre-clinical biotechnology company headquartered in Medford, Massachusetts, focused on developing oral small molecule therapies for central nervous system and neurodegenerative diseases. The company targets novel mechanisms to create neurorestorative treatments for CNS disorders.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Muna Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Muna Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →